In allo-SCT, mycophenolate mofetil (MMF) is increasingly being used for prevention of GVHD because of less mucositis and faster neutrophil engraftment compared with MTX. 1 Three-times daily administration of MMF after allo-SCT has been demonstrated to maintain higher plasma levels of the active metabolite, mycophenolic acid (MPA), and possibly result in better clinical outcomes. [2] [3] [4] We retrospectively analyzed the effect of MMF dosing on neutrophil engraftment in single-unit cord blood transplantation (s-CBT) and unrelated BMT.
A total of 45 patients who received allo-SCT using MMF between November 2004 and November 2009 were studied. The patient characteristics are shown in Table 1 . All patients received allo-SCT as a primary setting. MMF was administered orally for GVHD prophylaxis in combination with tacrolimus from 4 to 6 h after allo-SCT from day 0 to day 30, and then the dose tapered depending on individual risk factors for GVHD as described previously. 5 Regardless of the stem cell source, MMF was administered twice a day (b.i.d.) at a dose of 17.5 mg/kg (range 12.2-26.0 mg/kg, maximum 3000 mg/day) or thrice a day (t.i.d.) at a fixed dose of 1000 mg (median 17.5 mg/kg, range 10.0-22.7 mg/ kg, total 3000 mg/day). Neutrophil engraftment was defined as the first of two consecutive days with an ANC of 40.5 Â 10 9 /l. Acute GVHD was graded according to the consensus grading scale. The cumulative incidence was calculated for neutrophil engraftment and acute GVHD by treating death as a competing event. All descriptive data were analyzed using the statistical package Prism 5.0 (GraphPad Software, San Diego, CA, USA).
Almost all patients, except two from the t.i.d. group receiving s-CBT, had successful neutrophil engraftment. One died of severe bacterial pneumonia before neutrophil engraftment, and the other encountered graft failure but restored autologous hematopoiesis. As shown in Table 1 , there was no significant difference in the median periods of neutrophil engraftment between the b.i.d. and t.i.d. groups of BMT. However, the intensive t.i.d. administration of MMF significantly delayed neutrophil engraftment in s-CBT, although there was no significant difference in the infused CD34 þ cell doses between the two groups ( Table 1) . MMF-induced myelosuppression has been seen during the treatment of acute GVHD. 6 Neutropenia associated with increased plasma MPA levels has been reported in systemic sclerosis. 7 MMF has been reported to inhibit the proliferation of vascular smooth muscle cells and fibroblasts. 8, 9 The cumulative incidences of grade II-IV acute GVHD in the b.i.d. and t.i.d. groups of s-CBT were 25 and 8% (log-rank P ¼ 0.258), respectively. Although intensive MMF administration resulting in strong immunosuppression may prevent graft rejection and severe acute GVHD, it might also inhibit the growth of donor hematopoietic cells. Such an undesirable effect might be more apparent in s-CBT, in which the CD34 þ cell numbers are small. These preliminary observations require confirmation, and randomized studies are necessary to determine the best dosing scheme for MMF.
